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ABSTRACT 
Background: Epidemiologic data on the role of metabolic syndrome on prostate cancer 
risk is inconsistent, and only one case-control trial has examined the combined 
relationship of metabolic syndrome and vitamin D deficiency.  
Objective: To determine the association of metabolic syndrome and vitamin D 
insufficiency on prostate cancer.  
Design: De-identified data for blood pressure, BMI, triglyceride, HDL, serum glucose, 
25-hydroxyvitamin D, and prostate cancer diagnosis were collected retrospectively from 
the HERON database on 104 men who received care at the University of Kansas Medical 
Center from 2003 to 2012. Logistic regression was used to determine the association 
between metabolic syndrome, vitamin D concentration and prostate cancer.  
Results: Vitamin D insufficiency was not significantly associated with prostate cancer 
and did not have a significant interaction with metabolic syndrome. High HDL (>60 
mg/dL) was protective against prostate cancer (p=0.04, OR .173) compared to normal 
HDL (40-60 mg/dL). High systolic blood pressure (>135 mmHg) increased the risk of 
prostate cancer among general age-matched controls (p=0.03 OR=2.58) compared to 
normal blood pressure (<135 mmHg). No other elements of metabolic syndrome or the 
clustering of elements together were significant.  
Conclusion: Metabolic syndrome with vitamin D insufficiency did not prove to be 
significantly associated with prostate cancer diagnosis. Only elevated systolic blood 
pressure (>135 mmHg) was significantly associated with an increased risk of prostate 
cancer, whereas high HDL was associated with a protective effect.  
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Chapter I: Introduction 
 With an estimated 241,740 new diagnoses in 2012, prostate cancer remains the 
most common non-cutaneous cancer and leading cause of cancer death in men in the 
United States. In 2012 prostate cancer caused an estimated 28,170 deaths (1). The inter-
relationships among disease states and prostate cancer development are not well 
understood. Internationally, variations in the prevalence of chronic diseases, including 
prostate cancer, suggest lifestyle factors may contribute to development. Metabolic 
syndrome is a clustering of several risk factors resulting from obesity and insulin 
resistance. It is much more prevalent in Western societies than in Eastern societies, a 
trend that is also true in prostate cancer prevalence. The potential role of metabolic 
syndrome in the development of prostate cancer is unclear due to inconsistent results 
among studies. Variation in vitamin D status among participants may explain some of the 
variation seen between studies. Vitamin D and metabolic syndrome both share common 
signaling pathways that together may influence the development of prostate cancer. 
However, only one study has examined the combined role of metabolic syndrome and 
vitamin D status on prostate cancer risk.  An increase in prostate cancer risk in patients 
with both metabolic syndrome and vitamin D deficiency, as compared to men without 
metabolic syndrome and adequate vitamin D levels was reported in this study (2).  
 The current trends of rising obesity and low vitamin D levels within the U.S. may 
put men at greater risk for prostate cancer and identify a possible mechanism for prostate 
cancer prevention.  The Center for Disease Control estimated that 35.1% of American 
men met the criteria for Metabolic Syndrome in 2006 (3). An estimated one fourth of the 
U.S. population were at risk for vitamin D inadequacy in 2001-2006, and eight percent 
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were at risk for deficiency (4). Vitamin D status, according to serum 25(OH) Vitamin D 
concentrations is outlined in Table 1. Older adults (over 51 years of age) are also at 
increased risk of vitamin D deficiency (4). 
Table 1. Vitamin D status, according to IOM standards for serum 25(OH) vitamin D 
concentration.  
Category Serum Concentration Range (nmol/L) 
Risk deficiency with leading to osteomalacia <30 
Risk inadequacy for bone and overall 
health 
30-50  
Adequate for bone and overall health 50-125 
Potential adverse effects ≥125  
 
Statement of Purpose 
 The aim of this study was to determine the association between metabolic 
syndrome with vitamin D insufficiency and prostate cancer by testing the following aims. 
1. Investigate the association between metabolic syndrome and vitamin D inadequacy 
(<50 nmol/mL) on prostate cancer. I hypothesize that men with metabolic syndrome 
and vitamin D insufficiency will have a higher incidence of prostate cancer than 
men without metabolic syndrome who have adequate vitamin D.  
2. Evaluate interaction between individual risk factors for metabolic syndrome and 
vitamin D (see Table 2) on incidence of prostate cancer, and the association 
between each risk factor.   
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Table 2. Risk factors for Metabolic Syndrome in Males (according to ATP III 
guidelines) (5) 
Risk Factor Defining Level 
Abdominal Adiposity Waist Circumference >102 cm (>40in) 
Triglycerides ≥150 mg/dL 
HDL <40 mg/dL* 
Blood Pressure ≥130/≥85 mmHg 
Fasting Glucose ≥110 mg/dL 
*40-60 mg/dL, and >60 mg/dL were added as HDL categories during the analysis.  
My hypothesis is that the presence of risk factors associated with metabolic syndrome 
along with vitamin D insufficiency will correlate to an increased risk of developing 
prostate cancer. This study will provide the estimated risk of developing prostate cancer 
based on the presence of metabolic syndrome and vitamin D insufficiency. The 
knowledge of prostate cancer development gained through coordination and 
implementation of this project will help me counsel cancer patients as a future clinical 
oncology dietitian and guide the generation of future hypotheses.  
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Chapter II: Literature Review 
Introduction 
Metabolic syndrome is a cluster of risk factors centered on obesity, a growing 
epidemic in the United States (3). These risk factors are described with inclusion of 
clinical characteristics in Table 2. Clinical identification of metabolic syndrome uses 
criteria set by the National Cholesterol Education Program, Adult Treatment Panel III 
(ATP III). Three of the five characteristics must be present to diagnose metabolic 
syndrome. Those that have metabolic syndrome have increased risk of cardiovascular 
disease, as well as other chronic diseases (5).  
Prostate cancer risk based on the presence of metabolic syndrome remains 
uncertain due to the heterogeneity between studies conducted, including: the populations 
studied, the criteria used to assess metabolic syndrome (diagnoses, anthropometric 
measurements, laboratory measures, etc.), and the end points measured (PSA dynamics, 
histologically confirmed prostate cancer, prostate cancer related death). One possible 
explanation for the mixed data separate from the heterogeneity may be the interaction of 
vitamin D with metabolic syndrome.  
 Vitamin D insufficiency and metabolic syndrome both share common signaling 
pathways that when combined, may produce a synergistic effect. Vitamin D and 
Lipoproteins have been demonstrated to form common compounds with the same 
receptor resulting in differing translational effects (6). The combination of metabolic 
syndrome with vitamin D insufficiency may result in an additive effect. This may be one 
reason for the inconsistencies among studies, as only one study to date has examined the 
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risk of developing prostate cancer (2) with the combination of metabolic syndrome and 
vitamin D insufficiency. 
Metabolic Syndrome and Prostate Cancer Risk 
Mechanism:  Metabolic syndrome may interact to promote prostate cancer through 
several pathways. As previously described each individual risk factor involved may 
contribute to an increased risk of prostate cancer, and together may provide a synergistic 
effect. One hypothesis centers around the role of insulin resistance and the increase in 
insulin growth factor-I (IGF-1), leading to increased cell proliferation and growth (7). 
Insulin resistance is often seen with obesity, which as described leads to hormonal 
changes (decreasing testosterone and sex-hormone binding globulin (SHBG), and 
increasing estradiol concentration) which could promote different prostate cancer types 
(8). The influence of lipid raft signaling from altered lipid homeostasis and increase in 
androgen signaling from sympathetic nervous system signaling with the effects of obesity 
and insulin resistance is not fully understood. Further research is needed to determine if 
individual risk factors have an additive effect on risk of developing prostate cancer. 
Evidence: Current evidence on the role of metabolic syndrome and the incidence of 
prostate cancer is inconsistent, however several studies have shown a significantly 
increased risk of prostate cancer due to the additive effect of multiple risk factors. Two 
case controls studies show significant increases in prostate cancer risk with the 
combination of at least three elements (9-11). Although, one study found statistical 
significance only in African-Americans but not Caucasians (11). Two cohort studies also 
showed significant increases in risk with three or more risk factors, but failed to show 
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significance with individual risk factors (2, 12). However, not all studies coincide with 
these findings.  
 Several studies have shown a lack of association or a protective effect between 
metabolic syndrome and prostate cancer. Two large cohorts failed to show an increased 
risk from a combination of three risk factors (13, 14). One cohort study even found a 
decreased risk of prostate cancer (RR 0.77, CI 0.6-0.98) with metabolic syndrome (14). 
The authors hypothesize that the reduced production of insulin after damage to the 
pancreas from long term Type II diabetes coincides with the reduction in risk.  The 
discrepancy in findings among research studies may be explained by their heterogeneity 
as described earlier.  
 The heterogeneity in study design may have resulted in the diverging overall 
findings. Study designs differed in populations studied, some restricting race, others 
using European populations who don’t routinely screen with prostate specific antigen 
(PSA) which may have increased the rate of advanced cancers. Other factors include the 
variance in measurement of risk factors (diagnosis vs. standardized measurements), 
variance in risk factors collected (collecting only three selected risk factors vs. 
information on all five), standards used for diagnosing metabolic syndrome (ATP III 
guidelines, vs. alternate standards), and study design (cross-sectional vs. cohort). These 
factors limit the generalizability of the studies. Another possible explanation for the 
variability among metabolic syndrome studies on the incidence of prostate cancer may 
involve the vitamin D status of the participants.  
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Vitamin D, Metabolic Syndrome, and Prostate Cancer Risk 
Mechanism: An interaction between metabolic syndrome and vitamin D insufficiency 
may come from shared signaling pathways between the two factors. Obesity results in 
increases in lipoprotein remnants. These remnants act as ligands for peroxisome-
proliferator-activated receptors (PPAR) especially PPAR-γ (15). PPARs are known to 
influence adipogenesis, lipid metabolism, insulin sensitivity, and inflammation in relation 
to metabolic syndrome (2).  PPAR-γ and vitamin D receptor both bind to a common 
receptor, Retinoid X receptor  forming heterodimers which are highly expressed in 
prostate tissue (6). These heterodimers are known to influence each other’s target gene, 
regulating prostate cell growth and apoptosis (6, 15). Active vitamin D has also been 
shown to regulate IGF leading to decreased IGF-II expression, and increased production 
of insulin-like growth factor binding protein III (16). This complex relationship of 
signaling pathways is not fully understood but suggests vitamin D status may play a role 
in metabolic syndrome and prostate cancer development.  
Evidence: To my knowledge only one study has examined the combined effect of 
metabolic syndrome with vitamin D status demonstrating a positive relationship with risk 
of prostate cancer. A recent cohort study found that elevated blood pressure, increased 
body mass index (BMI), and low HDL increased the risk of prostate cancer (OR 3.36, p 
0.02) (2). Men who were also vitamin D deficient (<40 nmol/L), had an eight fold 
increase in risk (OR 8.03 p=0.05) compared to men without vitamin D insufficiency and 
free of metabolic syndrome (2).  
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Cholesterol and Prostate Cancer Risk 
Mechanism: Cholesterol may influence several possible pathways leading to the 
initiation and progression of prostate cancer. The prostate is a cholesterol rich tissue; 
therefore elevated serum cholesterol may result in the accumulation of cholesterol in the 
cell membrane forming large lipid rafts. These lipid rafts have been shown to have pro-
carcinogenic cell signaling effects (17). The Akt and Sonic hedgehog pathways are 
cholesterol sensitive and are related to prostate carcinogenesis (17). In vitro reduction of 
cholesterol has been shown to induce apoptosis in prostate cancer cell lines through 
inhibition of phosphatidylinositol 3-kinase/Akt pathway (18, 19). The interaction 
between these pathways is not fully understood and is still being investigated.  
Evidence:  Due to the aforementioned mechanisms, elevated serum cholesterol levels 
may also be a factor in prostate cancer development, although it is not a criterion of 
metabolic syndrome. Several studies have shown a positive association between 
cholesterol and prostate cancer risk. A large cohort study showed that total cholesterol 
greater than 240 mg/dL compared to less than 160 mg/dL was positively associated with 
prostate cancer (HR 1.24, 95% CI 1.07-1.44), but lacked evaluation based on cancer 
stage/grades (20). A different cohort study that incorporated grade analysis also found a 
positive association between elevated cholesterol (>240 mg/dL vs. <200 mg/dL) and 
overall prostate cancer, as well as advanced prostate cancer (stage 3) (21).   In a third 
study, Platz et al (22) found a decreased risk of prostate cancer with low total cholesterol 
level, especially in organ confined prostate cancer.  
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Not all studies that have been done on cholesterol and prostate cancer have found 
similar results. Smith et al (23) found no association between serum cholesterol and 
prostate cancer in a smoking population.  In addition, the Campaign Against Cancer and 
Stroke cohort shows a decreased risk ( HR 0.68, CI 0.4-1.18) of prostate cancer with 
elevated cholesterol (>240 mg/dL) compared to non-elevated cholesterol (<240 mg/dL) 
(24). These discrepancies in results may be due to the variability in serum cholesterol 
levels compared. In addition, variations also existed between participant populations; 
smoker vs. non-smokers, racial diversity, and inclusion and exclusion criteria.  
Elevated Triglycerides and Prostate Cancer Risk 
Mechanism: Elevated triglycerides may increase prostate cancer risk through 
lipoprotein signaling pathways. Hypertriglyceridemia results in the accrual of very low-
density lipoproteins, chylomicrons, which are hydrolyzed, producing remnant 
lipoproteins. Lipoprotein remnants result in activation of Akt signal transduction, and 
mitogen-activated protein kinases, which increase prostate cancer cell proliferation (25).  
However, it is not well understood at what concentration similar results would occur in 
human subjects.  
Evidence:  The impact of elevated triglyceride levels on prostate cancer risk varies 
among the population studied and may only be significant with the presence of another 
chronic disease risk factor. A large cohort study found no significant association with 
high triglycerides and prostate cancer alone, but high triglycerides combined with high 
fasting glucose showed a significantly increased risk (HR 1.23, CI 1.01-1.48, 
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Triglycerides >1.71 mmol/L, Glucose >100 mg/dL) (26). The significance of these two 
risk factors with metabolic syndrome provides evidence for the additive effects seen.  
 Other studies have shown significant results with triglycerides alone. One study 
found significant associations with elevated triglycerides and prostate cancer in men 60-
69 years (OR 2.10, CI 1.31-3.37) and 70 or greater (OR 1.91, CI 1.03-3.53), but not 
among men younger than 60 years (27). Excluding subjects that used statins in either 
study did not significantly alter the results. However, the significance may be explained 
by the increased risk of prostate cancer from age alone. An Austrian study found an 
increased risk for every log unit increase in triglycerides (28), providing evidence that the 
extent of triglyceride level, may increase your risk of prostate cancer.  Triglycerides are 
not the only serum lipid marker involved with metabolic syndrome; HDL is also a risk 
factor.   
Low HDL and Prostate Cancer Risk 
Mechanism: High Density Lipoprotein (HDL) has been hypothesized to provide 
protection from prostate cancer due to its role in removing cholesterol from tissues, and 
ultimately from the body. HDL has also been shown to be anti-inflammatory, as it 
reduces circulating levels of inflammatory cytokines (29). In addition, preliminary 
research has also shown HDL to decrease tumor necrosis factor alpha (TNF-α) in animal 
models, decreasing tissue damage, which may help prevent prostate cancer initiation (30). 
The complete role of HDL in oncogenesis is unclear and further research is needed to 
determine possible interactions that may provide protection.  
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Evidence: The association with low HDL and prostate cancer risk is still not clear. 
One large Swedish cohort and one American case-control study found an inverse 
relationship between serum HDL concentration and prostate cancer risk (26, 31). An 
American study controlled for statin use, but found it had no effect on the association 
(31). Two case-control trials from America and Finland and one Norwegian cohort study 
found no significant association between HDL and prostate cancer (2, 13, 21). Several 
limitations may account for the variation in results. None of the studies controlled or 
accounted for dietary habits among participants and eating patterns greatly differ between 
Northern Europeans and Americans, which may have correlated to lipid profile changes. 
Few studies controlled for smoking habits among participants or included only smoking 
participants. Smoking has been identified to increase the risk of prostate cancer, and may 
have confounded the results. Further research with greater control of confounding 
variables is needed to determine if an association exists.  
Blood Pressure and Prostate Cancer Risk 
Mechanism:  Blood pressure is another risk factor of metabolic syndrome, which may 
contribute to an increased risk of prostate cancer. Prostatic growth has been shown to be 
the result of a balance of sympathetic and parasympathetic activity (32). Elevated blood 
pressure may contribute to onocogenesis through the increase in sympathetic nervous 
system activity, which may in turn result in increased prostatic growth (33).  The exact 
mechanism by which growth is stimulated is currently unknown.   
Evidence: One large cohort study of Norwegian men found a significant association 
between blood pressure and prostate cancer risk (34). They found a 4% increase in risk 
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for every 18.3 mmHg increase in systolic blood pressure, which remained even when 
excluding those on antihypertensive medication from analysis (34). Two cohort studies 
and one case-control study found no significant association with increased blood pressure 
and prostate cancer risk (35-37). Fitzpatrick et al (35), found  positive associations 
between blood pressure and heart rate with prostate cancer. However they observed 
inverse associations with antihypertensive medication use. Several limitations prevent 
comparison between these studies. Not all the studies controlled for use of anti-
hypertensive medications, which could confound the results of associations observed. 
Dietary patterns were unknown, duration of hypertension or treatments of hypertension 
were also not controlled, and family history of hypertension was not collected in all of the 
studies. The combined limitation of these studies warrants further research on the subject.  
Elevated Fasting Glucose and Prostate Cancer Risk 
Mechanism:  Elevated fasting glucose is a sign of insulin resistance, which plays a large 
role in metabolic syndrome, and may also have oncogenic properties. As described with 
metabolic syndrome, insulin resistance leads to an increase in IGF-1 (7). Elevated IGF-1 
has been found to be predictive of prostate cancer (7). It has also been demonstrated to 
increase cell proliferation and decrease apoptosis (38). Increases in circulating insulin 
have also been shown to decrease insulin-like growth factor binding protein (IGFBP), 
resulting in a larger concentration of circulating IGF. Together, the combination has been 
demonstrated to increase the risk of developing prostate cancer (7).  
Evidence: Studies examining the association of insulin resistance and prostate cancer 
vary according to the variable chosen to represent insulin resistance. In a cohort study of 
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men with benign prostatic hyperplasia, fasting glucose concentration was positively 
associated with prostate size (39). Nimptsch et al. (40) examined the role of glycemic 
index and glycemic load on prostate cancer risk based on food frequency questionnaires, 
but found no significant association with prostate cancer risk. However, the study relied 
on glycemic load which is highly dependent on the combination of foods eaten, and may 
not accurately reflect true blood glucose levels.  
 Several case-control and cohort studies have also used fasting glucose or presence 
of diabetes to classify insulin resistance. However, one cohort study found a positive 
association with fasting glucose level and prostate cancer risk (14). Type 2 diabetes is 
also another way to define insulin resistance. Three large cohort studies found no 
statistically significant association with blood glucose and prostate cancer risk, although, 
the studies varied in fasting and non-fasting blood glucose measurements (12, 13, 41). 
Three studies using self reported presence of diabetes found no statistically significant 
association with prostate cancer risk(9-11).  
 The generalizability of these studies remains difficult due to the heterogeneity 
between studies. The multiple criteria used to establish insulin resistance limits 
comparison between studies. Even studies using serum glucose are limited due to the 
difference in fasting or random glucose measures used. Type 2 diabetes reflects a more 
complex disease than insulin resistance alone and may not accurately reflect the role of 
insulin resistance in the development of prostate cancer. Further research with 
standardized measurements is needed to further explore this potential association.   
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Central Adiposity and Prostate Cancer Risk 
Mechanism: There are several hypotheses regarding the role of obesity in prostate 
cancer initiation and progression. Obesity represents a complex change in metabolic 
factors and also increases the risk of several of the other metabolic syndrome risk factors 
(insulin resistance, blood pressure, and altered lipid homeostasis) (42). Abdominal 
adiposity is often the focus of studies due to its known role in increasing hormone 
production (43). Obese men have been shown to have altered circulating hormone levels 
including decreased serum testosterone, decreased SHBG, and increased estrogen 
concentrations (44). Testosterone is converted to dihydrotestosterone (DHT) in the 
prostate which binds to androgen receptors promoting DNA synthesis and cell 
proliferation (45). One study found a decrease in testosterone to be protective only 
against non-aggressive prostate cancer, but resulted in an increased risk of aggressive 
cancer (8). Increased estradiol concentrations were also shown to be protective against 
non-aggressive prostate cancer (8). Further studies are needed to determine the complex 
relationship involved with hormonal changes involved with obesity and prostate cancer 
development.  
Evidence: A large amount of studies have used BMI as a marker of obesity, even 
though it is a nonspecific maker and does not differentiate between adipose tissue and fat 
free mass. Therefore, waist circumference and waist to hip ratio have been used to 
provide a more accurate tool for measuring obesity as well as abdominal adiposity. 
Several cohort studies including the Harvard Alumni Health Study, have found 
significant association between prostate cancer risk and measures of height, weight, BMI, 
waist to hip ratio, and waist circumference (46-48).  
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Hsing et al. (49) found a positive association with waist to hip ratio (>0.92 vs 
<0.86) and prostate cancer risk (OR 2.71, CI 1.66-4.41), but no significant association 
with BMI in a Chinese population of healthy weight men (average BMI 23.1). Two 
European cohorts found significant associations with waist circumference and waist to 
hip ratio and prostate cancer risk (50, 51). DeNunzio et al. (50) further divided men into 
categories based on obesity (BMI >30) and presence of central adiposity (Waist 
circumference >40 in). They found a large increase in prostate cancer risk in obese men 
without central adiposity, as well as those with or without obesity who have central 
adiposity. Inconsistencies may be due to differing study design, such as the varying 
markers of adiposity used (BMI, Waist Circumference, and Waist to Hip Ratio) and 
methods of collection (self-reported, standardized collection, self-reported weight trends 
through decades). 
 A meta-analysis on measures of obesity and prostate cancer risk found overall 
weak positive associations (rate ratios 0.96-1.12) with obesity and prostate cancer  (52). 
The study included 31 cohort studies and 25 case-control studies, which contained 
information on measures of adiposity and prostate cancer development or mortality. 
Results were stratified for BMI showing an increased overall risk (rate ratio 1.05 per 5 
kg/m
2
 increment, CI 1.01-1.08), increased risk of advanced prostate cancer (rate ratio 
1.12 per 5 kg/m
2
, CI 1.01-1.23), but no significant association was found with localized 
prostate cancer (52). There was also an increased risk based on waist circumference (rate 
ratio 1.03 per 10 cm increment, CI 0.99-1.07), and waist to hip ratio (RR 1.11 per 0.1 
increment, CI 0.95-1.30) but they were not significant (52). Continued work confirms 
positive associations with obesity and risk of advanced or metastatic cancer (53). Recent 
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evidence shows direct correlation between body shape and changes in IGFs and IGFBPs 
(53). The difference in the strength of association seen in these studies may be due to the 
heterogeneity of the population and methods used. BMI also fails to detect sarcopenic 
obesity, the loss of muscle mass and gain of fat mass, which affects this aging population 
and may prevent studies using BMI as a tool to see more significant results.   
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Chapter III: Materials and Methods 
Study Overview 
 A retrospective data set was compiled by searching electronic medical records, 
and the cancer registry database for patients at University of Kansas Hospital (KUH) 
using a medical informatics database. The primary aim was to determine if there is an 
association between metabolic syndrome with vitamin D insufficiency and prostate 
cancer. The secondary aim was to determine if there is an association of prostate cancer 
with each individual metabolic syndrome risk factor on incidence of prostate cancer and 
with interaction with vitamin D. 
Data Extraction 
 Participants were male patients of the University of Kansas Hospitals and Clinics 
from 2003-2012. Three cohorts of patients were extracted based on characteristics 
outlined in Table 3. All patients had at least one laboratory value for each measure to 
ensure metabolic syndrome and vitamin D status could be evaluated.  
HERON, the medical informatics database used, is an integration of data collected 
from the KUH electronic medical record (EMR), billing system, and national cancer 
registry, which includes clinical and biomedical data (54). The database was queried 
through use of the Informatics for Integrating Biology & the Bedside (i2b2) tool (version 
1.6). Search terms are outlined in Appendix A. This work was supported by a CTSA 
grant from NCRR and NCATS awarded to the University of Kansas Medical Center for 
Frontiers: The Heartland Institute for Clinical and Translational Research # 
UL1TR000001 (formerly #UL1RR033179). The contents are solely the responsibility of 
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the authors and do not necessarily represent the official views of the NIH, NCRR, or 
NCATS. 
University of Kansas Medical Center Human subjects training was completed 
prior to accessing the HERON database. Patient information was de-identified including 
a random date shift; therefore there was no direct contact with patients or their medical 
records. Use of de-identified data is exempt for approval by the Human Subjects 
Committee/Institutional Review Board. However, approval from the Data Request 
Oversight Committee was required, before the data set could be extracted. De-identified 
patient data sets were stored on secured servers within KUMC. No hard copies of the data 
set were produced. Participant division is illustrated in Figure 1. 
Table 3. Inclusion and Exclusion Criteria for the HERON Database Search 
Cohort 1 (Cases) Cohort 2 (Specific Controls) Cohort 3 (General Controls) 
Inclusion 
Histologically confirmed 
prostate cancer 
BMI  
Serum Triglycerides  
Serum HDL  
Blood Pressure 
Fasting glucose  
Serum 25(OH) Vitamin D  
Inclusion 
Age  
40-50 PSA >2.5 
50-60 PSA >3.5 
>60    PSA >6 
PSA:free PSA, or family 
history 
BMI  
Serum Triglycerides  
Serum HDL  
Blood Pressure 
Fasting glucose  
Serum 25(OH) Vitamin D  
Inclusion 
Age  
40-50 PSA <2.5 
50-60 PSA <3.5 
>60    PSA >4 <6 
PSA:free PSA, or family 
history 
BMI  
Serum Triglycerides  
Serum HDL  
Blood Pressure 
Fasting glucose  
Serum 25(OH) Vitamin D 
Exclusion* 
 Cancer other than 
prostate or skin 
cancer 
 Kidney disease 
 Liver disease 
Exclusion* 
 Cancer other than skin 
cancer   (basal or 
squamous cell 
carcinoma)  
 Kidney disease 
 Liver disease 
Exclusion* 
 Cancer other than skin 
cancer   (basal or 
squamous cell 
carcinoma)  
 Kidney disease 
 Liver disease 
* Determined by presence of appropriate International Classification of Diseases, 9
th
 edition 
codes within electronic medical records at KUMC.  
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Figure 1. Database participant counts 
 
 Lab values were based on physician orders and were analyzed by KUH 
laboratory. BMI was calculated based on recorded height and weight. Blood pressure was 
taken by nursing staff. Glucose measures were taken as part of a chemistry panel.   
Several criteria were used to develop cases and controls. National cancer registry 
data were used to verify histologically confirmed prostate cancer. Cases were classified 
826 participants 
Malignant Prostate 
Cancer 
48 participants 
Metabolic 
Syndrome 
21 participants 
Vit D insuficiency  
20 participants 
Vitamin D Suficient 
1 participants 
No Metabolic 
Syndrome 
27 participants 
Vit D insuficiency 
25 participants 
Vitamin D Suficient 
2 participants 
General Controls 
593 participants 
Metabolic 
Syndrome 
 230 patients 
Vit D insuficiency  
77 participants  
Vitamin D Suficient 
3 participants 
No Metabolic 
Syndrome 
489 patients 
Vit D insuficiency 
370 participants 
Vitamin D Suficient 
28 participants 
Specific Controls 
59 participants 
Metabolic 
Syndrome 
16 participants 
Vit D insuficiency 
15 participants  
Vitamin D Suficient 
1 participants 
No Metabolic 
Syndrome 
43 participants 
Vit D insuficiency 
37 participants  
Vitamin D Suficient 
6 participants 
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as men with clinically relevant prostate cancer. Histological type was taken from the 
cancer database. Surveillance Epidemiology and End Results (SEER) coding was used to 
classify cancer staging information. Control cohorts were divided by age-related PSA 
values as outlined in Table 3.   
Statistical Analysis 
The software program SPSS for Windows, version 20 (56) was used for all 
statistical analyses. Prior to initiating the outcome measures, the data was examined for 
distribution with particular attention to variable ranges, central tendency (mean and 
median), dispersion (standard deviation) and missing values.  The numbers of values 
recorded across the variables were highly inconsistent. e.g blood pressure measures were 
taken several times a day and also several days in a row while other measures (give 
example here) were measured only once in a while. This resulted in large number of 
missing values for some variables. To deal with this inconsistency, data were aggregated 
into one median measure for each variable per patient. Median was chosen to best capture 
the central value during the study period because median is not sensitive to extreme 
observations and outliers. Since our main aim was to study the association of these 
measures with the prostate cancer status (dichotomous: yes, no) of the subjects, we 
modeled these risk factors using their median values with the prostate cancer as outcome. 
Since the outcome variable is dichotomous we performed logistic regression analysis. A 
Pearson correlation matrix was compiled to determine correlation between variables. 
Such correlation allowed us to determine if a high linear correlation existed between the 
predictor variables. We noticed that there was high degree of correlation between glucose 
2010 and glucose 2011 and therefore we dropped glucose 2010 from the multiple logistic 
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regression model. Boxplots and histograms were constructed for both non-aggregated and 
aggregated data to examine the distribution of the data. The plots were consistent before 
and after aggregating the data. The plots are illustrated in Appendixes B-D. Boxplots and 
histograms were used to visualize cases and controls and determine distribution patterns 
of the variables.  
Prostate Cancer Risk Analysis 
 To determine the primary research question, the median values were used for 
metabolic syndrome characteristics and vitamin D as described above. T-test was run for 
each variable to assess significant differences between cancer and non-cancer cases.  
 Metabolic syndrome elements were also categorized based on ATP III metabolic 
syndrome criteria outline in Table 2, vitamin D was dichotomized as sufficient or 
insufficient base on IOM guidelines (55). Logistic regression models were built using 
prostate cancer as the dependent variable and metabolic syndrome criteria and vitamin D 
as categorical variables. Interactions between each metabolic syndrome variable and 
vitamin D were also tested using logistic regression models (i.e. diastolic and vitamin D). 
Chi-square test of deviance was used to assess the interaction of metabolic syndrome 
with vitamin D status. Test of interaction was performed for metabolic syndrome and 
vitamin D status as both continuous and categorical variables (categorized based on ATP 
III criteria). The analyses were also carried out for both the specific control group with 
age adjustment and for the general age matched control group. 
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Chapter IV: Results 
 Baseline demographic information is shown in Table 4. Age and HDL were the 
only two variables with significant difference between cases and controls. Our study 
found a large amount of participants with vitamin D insufficiency (89-94%). Metabolic 
syndrome occurred more among prostate cancer cases than in controls (42% vs. 27-32%) 
however the difference was not statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Mean values of PSA, DBP, SBP, BMI, Glucose, HDL, Triglyceride, and Vitamin D 
level among cases and controls and results of t-test 
Characteristic Prostate Cancer 
Cases n = 48 
High Risk Controls 
n = 59 
General 
Controls n=593 
Age, years, ±SD 
Years since diagnosis, ±SD 
70.9±8.3 
6.9±5.8 
65.9 ±23.8 
- 
66.6±8.5 
Race    
     White or Caucasian, No. 37 48 509 
     Black or African American, No. 9 5 53 
     American Indian Alaskan 
Native, No. 
0 0 1 
     Asian, No. 0 1 6 
     Native Hawaiian or Pacific 
Islander, No. 
1 4 1 
     Other, No. 5 1 24 
Prostate Specific Antigen, ng/mL 
(SD) 
1.7 (2.4) 5.55 (3.43) 1.18(0.9) 
Diastolic Blood Pressure, mmHg 
(SD) 
74.21 (7.62) 74.26 (7.76) 74.36(8.0) 
Systolic Blood pressure, mmHg 
(SD) 
129.55 (11.43) 129.60 (13.18) 125.4(12.1) 
Body Mass Index, kg/m2  (SD) 28.65 (5.22) 28.31 (4.94) 29.77(8.1) 
Glucose, mg/dL (SD) 108.62 (16.76)a 108.52 (19.26) 111.99(25.4)a 
HDL, mg/dL (SD) 43.27 (9.90) 49.62 (12.75)a 44.80(11.5) 
Triglyceride, mg/dL (SD) 129.30 (99.78) 107.69 (62.34) 121.06(71.44) 
Vitamin D, ng/mL (SD) 
     Sufficient, No. (%) 
     Insufficient, No. (%) 
32.10 (11.60) 
3 (6.3) 
45 (93.7) 
34.68 (11.86) 
7 (11.9) 
52 (88.1) 
33.22(11.1) 
36 (6.1) 
557 (93.9) 
Metabolic Syndrome, No. (%) 21(43.7) 16(27.1) 193(32.5)  
a  denotes significance between cohorts p<0.05.  
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The categorical logistic regression models using ATP III guidelines for diagnosis 
of metabolic syndrome showed no significant results for individual variables, interaction 
of individual variables with vitamin D, or number of diagnostic metabolic syndrome 
criteria. Test of interactions showed no significant associations.  
The analysis with specific high-risk control showed that the participants with high 
HDL concentration (>60 mg/dL) had a significantly reduced the incidence of prostate 
cancer (p=0.04, OR 0.173) compared to men with normal HDL concentration (40-60 
mg/dL). The odds of having prostate cancer for the people having high HDL 
concentration are one sixth of the odds of having the prostate cancer with normal HDL. 
No other significant results were found using specific controls in any of the other 
variables or tests for interaction with vitamin D.   
The logistic regression model with age-matched general controls found that the 
odds of having prostate cancer for the participants with a high systolic blood pressure 
(>130 mmHg) to be 2.6 times of odds of developing prostate cancer for participants with 
normal systolic blood pressure (<130 mmHg) (p=0.03). No other metabolic syndrome 
factors or vitamin D were found to be significant with age-matched general controls.   
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Chapter V: Discussion 
Implications 
 Our study found that high systolic blood pressure and high HDL concentration to 
significantly impact the incidence of prostate cancer. Only one other study to date has 
examined the dual relationship, which found HDL to be mildly protective and a 
clustering of metabolic syndrome factors with vitamin D deficiency to greatly increase 
the risk of prostate cancer. Our study represents only a small population of men residing 
in the Kansas City metropolitan area. Further prospective studies are needed to determine 
if an association exists.  
Vitamin D insufficiency was found in almost all of the participants (94%) in the 
study. This is a stark contrast to the Institute of Medicine reports that suggest 25% of the 
population is at risk of insufficiency (55). The low numbers of participants with sufficient 
vitamin D may have limited our ability to find significant associations with prostate 
cancer. Sampling bias may also have occurred as a result of physicians only testing those 
who are at risk of deficiency, as Vitamin D testing is not often reimbursed by insurance.   
 Optimal levels of HDL (>60 mg/dL) were found to significantly decrease the 
incidence of prostate cancer compared to men with normal HDL concentration (40-60 
mg/dL). Evidence of the protective effect of HDL on prostate cancer is not clear. To date, 
two studies have found HDL concentration to be protective against prostate cancer (26, 
31). Higher HDL may provide the protection seen by significantly reducing circulating 
cholesterol and inflammatory cytokines, resulting in decreased incidence. These finding 
provide further evidence that HDL may be protective against prostate cancer.  
25 
 
 
 
 This study found that systolic blood pressure was the only element within 
metabolic syndrome to have a statistically significant association with prostate cancer, 
but this relationship was not observed with specific controls. Previous studies on blood 
pressure have yielded inconsistent results depending on controls for anti-hypertensive use 
(35-37). A major limitation is the inability to control for home medication use. Another 
limitation is that most blood pressure records are the result of inpatient stays, which may 
not accurately reflect true resting blood pressure. Further interpretation cannot be made 
without the ability to control for these cofactors.  
Strengths and Limitations 
This study has many strengths. It used only cases with histologically confirmed 
prostate cancer verified with the national cancer registry data. De-identified data helped 
protect the security of patient information while still allowing for investigational 
research. The study was one of the first to use datasets from HERON for a retrospective 
study, and helped aid in the development of the data set request process and i2b2 
development. 
The use of retrospective data in a case-control study inherently introduces many 
limitations. The reliance of previously existing laboratory measures made it impossible to 
ascertain all five metabolic syndrome criteria and vitamin D concentration at one point in 
time. Therefore true ascertainment of metabolic syndrome was not established, however 
it was assumed that these variables over time could still have a significant impact on the 
development of prostate cancer. Although ATP III criteria uses waist circumference for 
diagnosis of obesity, waist circumference was only recorded in the EMR in about 10% of 
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participants. BMI was used as a surrogate measure of obesity, but does not reflect body 
composition directly. Sarcopenic obesity, a common problem among prostate cancer 
survivors, is not detected by BMI. Fasting glucose was also not widely recorded in the 
EMR, therefore a glucose measurement from a chemistry panel had to be chosen which 
may not represent a true fasting state from all participants. Using matched case controls 
based on seasonal vitamin D analysis was not possible due to the de-identification time 
shift.  
 The sample size of this study was limited by the availability of retrospective data 
from the KUH hospital system, and lacks sufficient power to determine risk of 
developing prostate cancer. However, we obtained patterns and estimates of risk on 
developing prostate cancer.  Although HERON contains a wealth of information, most of 
it is a mixture of laboratory data from 2003 to the present. This condensed the length of 
the trial to roughly four years, which limits the ability to accurately reflect the possible 
association that chronic conditions such as metabolic syndrome could have on the 
development of prostate cancer.   
Conclusion 
 Clumping of metabolic syndrome elements and interaction with Vitamin D was 
not found to be associated with prostate cancer. Optimal HDL (>60 mg/dL) was found to 
be protective against prostate cancer. Systolic blood pressure was found to be a 
significant risk factor for prostate cancer in age-matched controls, however the inability 
to control for medication use limits this data. Further prospective research is needed to 
confirm if further associations exist. Medical informatics tools, like HERON, represent a 
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wealth of information that is constantly growing and evolving to meet the needs of 
research.  
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APPENDIX A. HERON Search Term  Criteria  
 
Table 3. HERON Search Criteria 
Group Terminology 
1 
 
 Male 
 
2 
 
 BMI 
3 
 
 
 Diastolic 
 Systolic 
4 
 
 Triglyceride 
5 
 
 HDL 
6  PSA 
 Histologically confirmed prostate cancer 
 Family history of malignant neoplasm of the prostate 
7  Glucose 2010 
 Glucose 2011 
 Glucose Fasting 
8 
 
 Vitamin D (25-OH) Total 
9 (excluding)  Malignant Neoplasms of bone, breast, skin, digestive organs, lip, oral 
cavity, pharynx, lymphatic, hematopoietic, respiratory, and unspecified 
sites 
 Cirrhosis of liver 
 Liver failure 
 Chronic renal failure 
Renal failure, uspecified 
The term “and” was applied between group terms, within groups the term 
“or” was applied 
 
 
 
 
 
 
 
33 
 
 
 
APPENDIX B. Pearson Correlation Matrix 
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APPENDIX C. Independent Variable Boxplots 
Diastolic boxplot     Systolic Boxplot 
  
 BMI Boxplot     HDL Boxplot 
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Glucose Boxplots 
 
Triglyceride Boxplot    Vitamin D Boxplot 
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APPENDIX D. Categorical Case/Control boxplot comparison 
 
Diastolic case control categorical boxplots comparison 
 
 
Systolic case control categorical boxplots comparison 
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BMI case control categorical boxplots comparison 
 
Glucose case control categorical boxplots comparison 
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HDL case control categorical boxplots comparison 
 
Triglyceride case control categorical boxplots comparison 
 
 
 
 
 
39 
 
 
 
 Vitamin D case control categorical boxplots comparison 
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APPENDIX E. Descriptive statistics of baseline participants.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary of Independent Variables   
Variable N Minimum Maximum Mean SD 
BMI 107 20.06 47.45 28.460 5.05 
Triglycerides 107 32.00 662.5 117.388 81.599 
HDL 107 27.00 79.00 46.776 11.938 
Blood Pressure 
     Diastolic 
     Systolic 
 
107 
107 
 
56.00 
105.00 
 
97.50 
157.50 
 
74.238 
129.579 
 
7.658 
12.369 
Glucose 95 79.00 170.00 108.568 17.947 
Vitamin D 106 11.30 75.30 33.509 11.758 
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APPENDIX F. Overall Participant Independent Variable Characteristics 
 
Associations of levels of DBP, SBP, BMI, Glucose, HDL, 
Triglycerides, and Vitamin D on risk of prostate cancer 
Variable B (SE) P Odds 
Ratio 
 
Diastolic (mmgHg) >85  -
0.471(.852) 
0.58
0 
0.624  
Systolic (mmHg) >135 -0.790 
(.877) 
0.36
8 
0.454  
BMI (kg/m2) >28 -0.625 
(.561) 
0.26
5 
0.535  
Glucose (mg/dL) >110 0.601 (.869) 0.48
9 
1.825  
HDL (mg/dL) <40 -0.975 
(.766) 
0.20
3 
0.377  
Triglycerides (mg/dL) 
>150 
.024 (1.001) 0.98
1 
1.025  
Vitamin D <50 -.0782 
(.865) 
0.36
6 
0.457  
Categories compared to a normal reference range as described in 
Table 4 above. 
 
 
 
 
 
 
 
 
 
 
 
 
